Centiva Capital LP bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,265 shares of the medical research company's stock, valued at approximately $1,431,000.
Several other institutional investors and hedge funds also recently bought and sold shares of the business. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Charles River Laboratories International by 1.7% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company's stock worth $394,359,000 after purchasing an additional 31,359 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock valued at $346,821,000 after acquiring an additional 509,163 shares during the period. Earnest Partners LLC increased its position in shares of Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company's stock valued at $207,507,000 after acquiring an additional 110,725 shares during the period. Marshall Wace LLP increased its position in shares of Charles River Laboratories International by 24.6% in the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company's stock valued at $170,615,000 after acquiring an additional 163,056 shares during the period. Finally, Sei Investments Co. increased its position in shares of Charles River Laboratories International by 8.6% during the second quarter. Sei Investments Co. now owns 624,800 shares of the medical research company's stock valued at $129,072,000 after buying an additional 49,451 shares during the period. 98.91% of the stock is owned by institutional investors.
Charles River Laboratories International Trading Up 0.0 %
CRL traded up $0.05 on Wednesday, reaching $199.35. 436,586 shares of the company traded hands, compared to its average volume of 619,583. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00. The firm has a fifty day simple moving average of $194.24 and a two-hundred day simple moving average of $204.24. The company has a market cap of $10.19 billion, a P/E ratio of 24.93, a price-to-earnings-growth ratio of 5.19 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.72 EPS. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.
Charles River Laboratories International announced that its Board of Directors has approved a stock repurchase plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its stock is undervalued.
Insider Transactions at Charles River Laboratories International
In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.30% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the stock. TD Cowen upped their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a report on Monday, November 11th. Bank of America downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $250.00 to $215.00 in a research report on Wednesday, October 2nd. CLSA downgraded shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research note on Thursday, November 7th. Finally, Barclays cut their target price on shares of Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating for the company in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $214.38.
View Our Latest Report on Charles River Laboratories International
Charles River Laboratories International Company Profile
(
Free Report)
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Further Reading
![Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&Symbol=CRL)
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.